VTVT vs. ACRV, CHRS, ADCT, VXRT, NKTX, PLX, GLSI, ACTU, DRUG, and CKPT
Should you be buying vTv Therapeutics stock or one of its competitors? The main competitors of vTv Therapeutics include Acrivon Therapeutics (ACRV), Coherus BioSciences (CHRS), ADC Therapeutics (ADCT), Vaxart (VXRT), Nkarta (NKTX), Protalix BioTherapeutics (PLX), Greenwich LifeSciences (GLSI), Actuate Therapeutics (ACTU), Bright Minds Biosciences (DRUG), and Checkpoint Therapeutics (CKPT). These companies are all part of the "pharmaceutical products" industry.
vTv Therapeutics vs.
vTv Therapeutics (NASDAQ:VTVT) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, community ranking, earnings, analyst recommendations and valuation.
vTv Therapeutics has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Acrivon Therapeutics has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.
In the previous week, Acrivon Therapeutics had 4 more articles in the media than vTv Therapeutics. MarketBeat recorded 4 mentions for Acrivon Therapeutics and 0 mentions for vTv Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.65 beat vTv Therapeutics' score of -0.55 indicating that Acrivon Therapeutics is being referred to more favorably in the news media.
Acrivon Therapeutics' return on equity of -47.95% beat vTv Therapeutics' return on equity.
vTv Therapeutics received 319 more outperform votes than Acrivon Therapeutics when rated by MarketBeat users. However, 97.06% of users gave Acrivon Therapeutics an outperform vote while only 57.80% of users gave vTv Therapeutics an outperform vote.
17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are owned by institutional investors. 1.3% of vTv Therapeutics shares are owned by insiders. Comparatively, 8.5% of Acrivon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
vTv Therapeutics has higher revenue and earnings than Acrivon Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.
vTv Therapeutics presently has a consensus price target of $35.00, suggesting a potential upside of 150.54%. Acrivon Therapeutics has a consensus price target of $23.67, suggesting a potential upside of 318.88%. Given Acrivon Therapeutics' higher probable upside, analysts clearly believe Acrivon Therapeutics is more favorable than vTv Therapeutics.
Summary
Acrivon Therapeutics beats vTv Therapeutics on 12 of the 15 factors compared between the two stocks.
Get vTv Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
vTv Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VTVT) was last updated on 1/21/2025 by MarketBeat.com Staff
Free VTVT Stock Alerts